TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7972390

Group type: EXPERIMENTAL
Intervention: Chocolate bar
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: White chocolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cocoa capsules (pharmacological equivalent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 2537349

Group type: EXPERIMENTAL
Intervention: Fish oil (10 capsules/day, 1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (10 capsules of 50% olive oil, 50% corn oil)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control
Number of subjects: 108
Study: 4557030

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 63

Group type: COMPARATOR
Intervention: Furazolidone
Number of subjects: 63
Study: 30609978

Group type: EXPERIMENTAL
Intervention: Mobile app and wearable device users
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mobile app-only users
Number of subjects: 60

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 60
Study: 28285749

Group type: EXPERIMENTAL
Intervention: Commercially delivered 12-week lifestyle behavioral program
Number of subjects: 88

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 88
Study: 26271843

Group type: EXPERIMENTAL
Intervention: Aphakic contact lens (CL)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Fellow eyes (Control)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Treated eyes with glaucoma
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Treated eyes with glaucoma suspect
Number of subjects: 114
Study: 24189171

Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine with sorafenib 400mg bid (arm A)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine without sorafenib (arm B)
Number of subjects: 114
Study: 22848045

Group type: EXPERIMENTAL
Intervention: Bed Rest (BR) for 8 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bed Rest (BR) for 35 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Second Bed Rest campaign
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bed Rest (BR)
Number of subjects: 9
Study: 19392995

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for pollen allergens
Number of subjects: 0
Study: 17316169

Group type: EXPERIMENTAL
Intervention: Quetiapine 200mg/day
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Quetiapine 100mg/day
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study: 15062892

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) for 4 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Health education control for 4 months
Number of subjects: 50
Study: 11577374

Group type: EXPERIMENTAL
Intervention: Voriconazole (200 mg, b.i.d.)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 391
Study: 9850026

Group type: EXPERIMENTAL
Intervention: BEACOPP (both standard and escalated dose)
Number of subjects: 505

Group type: COMPARATOR
Intervention: COPP/ABVD
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Baseline BEACOPP
Number of subjects: 505
Study: 7720940

Group type: EXPERIMENTAL
Intervention: 3 months nafarelin followed by 3 months of placebo (n = 91)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: 6 months nafarelin (n = 88)
Number of subjects: 179
Study: 2404528

Group type: EXPERIMENTAL
Intervention: BAVC regimen (BCNU, amsacrine, VP‐16 (etoposide) and Ara‐C)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CY + TBI regimen (cyclophosphamide/total body irradiation)
Number of subjects: 39
Study: 7401269

Group type: EXPERIMENTAL
Intervention: Elemental diet prepared as Jello
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elemental diet prepared as frozen Tang
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elemental diet prepared with Flavor Packets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elemental diet prepared as Kool-Aid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Product B
Number of subjects: 0
Study: 31810064

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise Training (MICE)
Number of subjects: 20
Study: 31175583

Group type: EXPERIMENTAL
Intervention: Low-fat diet pattern
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary quality measured by Healthy Eating Index score
Number of subjects: 0
Study: 28589965

Group type: EXPERIMENTAL
Intervention: Exposure treatment (2 sessions)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No-treatment (control)
Number of subjects: 47
Study: 25883130

Group type: EXPERIMENTAL
Intervention: Safe Sibs program (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 23764690

Group type: EXPERIMENTAL
Intervention: Gradual titration of paroxetine (2.5 mg on alternate days up to 10 mg in 7 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Abrupt initiation of paroxetine (10 mg)
Number of subjects: 50
Study: 21425721

Group type: EXPERIMENTAL
Intervention: Exercise every day (G1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Exercise three days per week (G2)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Exercise plus abdominal training three days per week (G3)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 68
Study: 19918629

Group type: EXPERIMENTAL
Intervention: Chest compression
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Air stacking
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined technique (air stacking and chest compression)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Baseline (no intervention)
Number of subjects: 28
Study: 16821647

Group type: EXPERIMENTAL
Intervention: New didanosine formulation (100 mg tablets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional didanosine formulation (100 mg tablets)
Number of subjects: 0
Study: 12778041

Group type: EXPERIMENTAL
Intervention: Classic ketogenic diet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MCT ketogenic diet
Number of subjects: 30
Study: 11372387

Group type: EXPERIMENTAL
Intervention: Budesonide combined with terbutaline
Number of subjects: 42

Group type: COMPARATOR
Intervention: Terbutaline with placebo (control group)
Number of subjects: 42
Study: 2064401

Group type: EXPERIMENTAL
Intervention: Topical vitamin E solution (DL-alpha-tocopherol in dimethyl sulfoxide) applied to three nails for 6 months
Number of subjects: 1

Group type: COMPARATOR
Intervention: Dimethyl sulfoxide only applied to three nails for 6 months
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Topical vitamin E solution applied to all nails for an additional 6 months after initial treatment
Number of subjects: 1
Study: 6133970

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 723

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 723
Study: 30172649

Group type: EXPERIMENTAL
Intervention: Vedolizumab (VDZ)
Number of subjects: 193
Study: 29996720

Group type: EXPERIMENTAL
Intervention: pl-VEGF165
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 27265893

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 2806
Study: 23990336

Group type: EXPERIMENTAL
Intervention: Automated call group (n=26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Health information group (n=24)
Number of subjects: 50
Study: 21927808

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (CP) using passive expiratory techniques
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no CP)
Number of subjects: 99
Study: 19906801

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (120 mg/d)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (80 mg/d)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 17989574

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (ITD) injections (0.3 mL on days 1, 3, and 5) plus 48 mg methylprednisolone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Methylprednisolone alone (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (ITD) injections
Number of subjects: 120
Study: 16009663

Group type: EXPERIMENTAL
Intervention: Incident cerebrovascular events
Number of subjects: 5804

Group type: EXPERIMENTAL
Intervention: Non-fatal myocardial infarction
Number of subjects: 5804

Group type: EXPERIMENTAL
Intervention: Incident vascular events
Number of subjects: 5804
Study: 12444816

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (50 mg/day)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Bromazepam (6 mg/day)
Number of subjects: 334
Study: 10539823

Group type: EXPERIMENTAL
Intervention: Cycle exercise (40 minutes, 30 minutes at 60% of maximal oxygen consumption)
Number of subjects: 18
Study: 8542863

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 2

Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 2
Study: 2288653

Group type: EXPERIMENTAL
Intervention: 3 megaunits of rIFN a‐2b s.c. thrice weekly for 4 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 58
Study: 30215171

Group type: COMPARATOR
Intervention: Nutritional sodium selenate (0.32 mg, 3 times daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Supranutritional sodium selenate (10 mg, 3 times daily)
Number of subjects: 40
Study: 30261375

Group type: EXPERIMENTAL
Intervention: Wallis interspinous spacer implantation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (lumbar discectomy without Wallis implantation)
Number of subjects: 77
Study: 26455957

Group type: EXPERIMENTAL
Intervention: Vegetable soup with added monosodium L-glutamate (0.5 g/100 ml)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control vegetable soup (without MSG)
Number of subjects: 68
Study: 24470436

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 6.5 mg/kg/day for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 23
Study: 24043137

Group type: EXPERIMENTAL
Intervention: Famitinib (doses increased from 4 to 30 mg, administered once daily)
Number of subjects: 54
Study: 21105934

Group type: EXPERIMENTAL
Intervention: Life skills instruction/training in school
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Life skills training out of school
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Receipt of life skills instruction in school
Number of subjects: 0
Study: 18838929

Group type: EXPERIMENTAL
Intervention: Isotonic fluids (NaCl = 140 mEq/L)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Hypotonic fluids (NaCl <100 mEq/L)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both isotonic and hypotonic fluids
Number of subjects: 122
Study: 16905851

Group type: EXPERIMENTAL
Intervention: Ribomunyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 30
Study: 12802717

Group type: EXPERIMENTAL
Intervention: Standardized phytodrug from Solanum chrysotrichum
Number of subjects: 101

Group type: COMPARATOR
Intervention: 2% ketoconazole
Number of subjects: 101
Study: 11038481

Group type: EXPERIMENTAL
Intervention: Cancer support organizations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complementary therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informational resources
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support organizations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Professional services
Number of subjects: 0
Study: 8898646

Group type: EXPERIMENTAL
Intervention: Wheat amylase inhibitor preparation (3.0 mg/mL)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Wheat amylase inhibitor preparation (4.5 mg/mL)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Wheat amylase inhibitor preparation (6.0 mg/mL)
Number of subjects: 3
Study: 1853700

Group type: EXPERIMENTAL
Intervention: alfentanil 10 micrograms/kg (A10)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: alfentanil 25 micrograms/kg (A25)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: alfentanil 50 micrograms/kg (A50)
Number of subjects: 68

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 68
Study: 7049504

Group type: EXPERIMENTAL
Intervention: Sulindac 400 mg once daily (at 9:00 P.M.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sulindac 200 mg b.i.d. (at 9:00 A.M. and 9:00 P.M.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sulindac 200 mg b.i.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sulindac 400 mg once daily
Number of subjects: 12
Study: 31861788

Group type: EXPERIMENTAL
Intervention: six-month structural and social food store intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: wait-list control condition
Number of subjects: 16
Study: 28299543

Group type: EXPERIMENTAL
Intervention: Short message intervention (SMS)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Group training
Number of subjects: 210
Study: 27392615

Group type: EXPERIMENTAL
Intervention: 11C-acetate PET/CT positive scan
Number of subjects: 121

Group type: COMPARATOR
Intervention: 11C-acetate PET/CT negative scan
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Highest SUVmax
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Total lipogenic activity (TLA)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Number of bone metastases
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tertile of TLA
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Postoperative Gleason score
Number of subjects: 121
Study: 24699132

Group type: EXPERIMENTAL
Intervention: Congruent preload (low-energy/liquid; high-energy/semi-solid)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Incongruent preload (low-energy/semi-solid; high-energy/liquid)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Repeated exposure to food
Number of subjects: 27
Study: 23114379

Group type: EXPERIMENTAL
Intervention: Active group (12-week structured exercise and nutrition program)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 100
Study: 20504163

Group type: EXPERIMENTAL
Intervention: Deltalog10(IQ12)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Deltalog10(IQ24)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DeltaIIP12
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DeltaIIP24
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Deltalog10(IQmax)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DeltaIIPmax
Number of subjects: 17
Study: 17997623

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control treatment (age-appropriate movie)
Number of subjects: 28
Study: 15889697

Group type: EXPERIMENTAL
Intervention: Enalaprilat (0.625 mg) IV infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: No ACE inhibition (control)
Number of subjects: 15
Study: 12171952

Group type: EXPERIMENTAL
Intervention: Anti-H pylori treatment (omeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1 g, all twice daily for one week followed by placebo for four weeks)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Anti-H pylori treatment (omeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1 g, all twice daily for one week followed by omeprazole 20 mg once daily for four weeks)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily for five weeks
Number of subjects: 660

Group type: COMPARATOR
Intervention: Placebo for five weeks
Number of subjects: 660
Study: 9570242

Group type: EXPERIMENTAL
Intervention: De Nol 120 mg q.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 2 weeks
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 2 weeks
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 1 week
Number of subjects: 129
Study: 7664546

Group type: EXPERIMENTAL
Intervention: CDP571 0.1 mg/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CDP571 0.3 mg/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CDP571 1.0 mg/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CDP571 3.0 mg/kg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 2750502

Group type: EXPERIMENTAL
Intervention: von Bahr screws
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Gouffon screws
Number of subjects: 214

Group type: COMPARATOR
Intervention: Hessel pins
Number of subjects: 214
Study: 831465

Group type: EXPERIMENTAL
Intervention: Two doses of vaccine (VV)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: One dose of vaccine followed by placebo (VP)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Two doses of placebo (PP)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: One or two doses of the vaccine
Number of subjects: 143
Study: 30618324

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 52
Study: 28678121

Group type: EXPERIMENTAL
Intervention: Treatment in the U.S.
Number of subjects: 2447

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 2447

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 2447

Group type: EXPERIMENTAL
Intervention: High-risk alcohol consumption
Number of subjects: 2447

Group type: EXPERIMENTAL
Intervention: Age <30 years
Number of subjects: 2447

Group type: EXPERIMENTAL
Intervention: Sustained polytrauma
Number of subjects: 2447

Group type: EXPERIMENTAL
Intervention: Gustilo-Anderson type-IIIA, B, or C fracture
Number of subjects: 2447
Study: 26218826

Group type: EXPERIMENTAL
Intervention: Cryolipolysis treatment (60-minute cycle followed by a 2-minute massage, then a second 60-minute cycle with 50% treatment area overlap)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cryolipolysis treatment
Number of subjects: 21
Study: 23150149

Group type: EXPERIMENTAL
Intervention: NAT2 genotype-guided treatment (PGx-treatment: 7.5 mg/kg for rapid acetylators, 5 mg/kg for intermediate acetylators, 2.5 mg/kg for slow acetylators)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Conventional standard treatment (STD-treatment: approx. 5 mg/kg of isoniazid for all)
Number of subjects: 172
Study: 21570335

Group type: EXPERIMENTAL
Intervention: Therapeutic Massage (TM)
Number of subjects: 16
Study: 19202343

Group type: EXPERIMENTAL
Intervention: Chlorhexidine powder (0.1%)
Number of subjects: 669

Group type: COMPARATOR
Intervention: Dry cord care (DC)
Number of subjects: 669
Study: 16669547

Group type: EXPERIMENTAL
Intervention: Prima Difesa (2 puffs per nostril, 4 times a day for 15 days) in Group A and B
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prima Difesa (1 administration) in Group C
Number of subjects: 80
Study: 12897580

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% QD added to pre-existing therapy (group A)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Latanoprost alone (group B)
Number of subjects: 136
Study: 11106218

Group type: COMPARATOR
Intervention: 5-mg nicotine patch (placebo)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: 15-mg nicotine patch
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Nicotine inhaler
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: 15-mg nicotine patch plus nicotine inhaler
Number of subjects: 446
Study: 8975347

Group type: EXPERIMENTAL
Intervention: Mepivacain Hydrochloride alone
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Mepivacain Hydrochloride with 20 mg of Triamcinolone Hexaacetonide
Number of subjects: 2
Study: 1582237

Group type: EXPERIMENTAL
Intervention: Midazolam (0.2 mg/kg intravenously) with flumazenil (0.1 to 0.2 mg intravenously)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.002 mg/kg intramuscularly)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nitrous oxide and oxygen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxygen only
Number of subjects: 100
Study: 3902677

Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine mesilate (DHT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Clonidine (CLO)
Number of subjects: 28
Study: 31790343

Group type: COMPARATOR
Intervention: Neuropsychological Assessment Battery, Screening Module (S-NAB) administered to the S-mTBI group with symptom and test coaching to simulate impairment.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Logistic regression model using seven raw scores from S-ATT and S-EXE subtests.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Two PVT formulas derived from logistic regression results.
Number of subjects: 72
Study: 30950970

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (DEX) implant (0.7 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Aflibercept (2 mg, 3 monthly injections as loading phase)
Number of subjects: 62
Study: 30005098

Group type: EXPERIMENTAL
Intervention: Natural ingredient‐based moisturizing cream
Number of subjects: 32

Group type: COMPARATOR
Intervention: Colloidal oatmeal moisturizing cream
Number of subjects: 32
Study: 26254019

Group type: EXPERIMENTAL
Intervention: Candesartan plus standard medical treatment
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Standard medical treatment alone
Number of subjects: 1145
Study: 24861549

Group type: EXPERIMENTAL
Intervention: Outpatient clinic follow-up every two months for 6 months with screening and targeted intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care by physician
Number of subjects: 204
Study: 22617632

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) administered in groups of six patients during 12 weekly sessions (n=25)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waiting-list control (n=18)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 43